Penetrium Bioscience Inc. (KOSDAQ:187660)

South Korea · Delayed Price · Currency is KRW

5,850.00

+750.00 (14.71%)

At close: Sep 4, 2026

Market Cap	320.37B +147.2%
Revenue (ttm)	9.74B -29.3%
Net Income	-20.10B
EPS	-475.02
Shares Out	54.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,938,682
Open	5,120.00
Previous Close	5,100.00
Day's Range	4,290.00 - 5,850.00
52-Week Range	2,300.00 - 21,500.00
Beta	2.29
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2026

About Penetrium Bioscience

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance serv... [Read more]

Industry Commercial Physical and Biological Research

Founded 2003

Employees 160

Stock Exchange KOSDAQ

Ticker Symbol 187660

Full Company Profile

Financial Performance

In 2024, Penetrium Bioscience's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.

Financial Statements